Actualités 17 avr 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
Aktuell 30 avr 2024 Johnson & Johnson eröffnet Innovation Hub in Allschwil Johnson & Johnson hat im Switzerland Innovation Park Basel Area den ersten J&J Innovation Hub auf dem europäischen Festland eröffnet. Es stellt e...
Aktuell 23 avr 2024 BGG aus China eröffnet Hauptsitz in Basel BGG richtet in Basel einen neuen globalen Hauptsitz ein und will von dort aus in Europa und den USA expandieren. Das Pekinger Unternehmen ist ein...
News 23 avr 2024 BGG from China opens headquarters in Basel BGG is establishing new global headquarters in Basel, from which it plans to grow in Europe and the USA. The Beijing-based company is a supplier ...
News 17 avr 2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
News 30 avr 2024 Johnson & Johnson opens Innovation Hub in Allschwil Johnson & Johnson has opened its first J&J Innovation Hub on the European mainland at the Switzerland Innovation Park Basel Area. This represents...
Aktuell 04 avr 2024 Galderma realisiert weltweit grössten Börsengang Die Kotierung an der Schweizer Börse hat Galderma knapp 2,3 Milliarden Franken eingebracht. Damit stellt das Pharmaunternehmen im ersten Quartal ...
Aktuell 20 oct 2023 Xlife Sciences wird Hauptaktionär von 4D Lifetec Xlife Sciences, ein börsennotierter Beschleuniger und Investor für innovative Gesundheitslösungen, beteiligt sich mit 23,3 Millionen Franken an d...
News 14 fév 2024 University of Fribourg discovers drug to combat age-related neuroinflammation Scientists at the University of Fribourg have uncovered a groundbreaking mechanism that could significantly mitigate age-related neuroinflammatio...
Aktuell 26 mar 2024 Zürcher Forschende machen Krebstherapie wieder wirksam Forschende der Universität Zürich und des Universitätsspitals Zürich haben herausgefunden, wie mutierte Blutkrebszellen wieder auf eine Immunther...
News 04 avr 2024 Galderma completes largest IPO on a global level in Q1 Galderma has banked nearly 2.3 billion Swiss francs following its listing on the SIX Swiss Exchange. The pharma firm was therefore responsible fo...
News 20 oct 2023 Xlife Sciences becomes main shareholder in 4D Lifetec Xlife Sciences, a listed accelerator and investor in innovative healthcare solutions, has made an investment totalling 23.3 million Swiss francs ...
Aktuell 13 mar 2024 PSI entwickelt neue Krebstherapie Forschende des Paul Scherrer Instituts (PSI) haben ein Radiopharmakon gegen metastasierende neuroendokrine Tumore entwickelt. Mit der erstmaligen...
News 18 oct 2023 BioArk Monthey’s third building signifies exponential growth in the life sciences sector With two decades under its belt, the BioArk site in Monthey continues to cement its position as a front-runner in life sciences.
News 26 mar 2024 Zurich researchers make cancer therapy effective again Researchers from the University of Zurich and University Hospital Zurich have discovered how mutated blood cancer cells can be made to respond to...
News 25 oct 2023 Mecaplast Swiss, 50 years of innovation in the canton of Fribourg With a rich history spanning five decades, Mecaplast Swiss has consistently proven itself as a leader in the plastic injection industry, particul...
News 10 jan 2024 The remarkable chemical-pharmaceutical industry in the canton of Valais For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation ...
News 13 mar 2024 PSI developing new cancer therapy Researchers from the Paul Scherrer Institute (PSI) have developed a radiopharmaceutical to combat metastatic neuroendocrine tumors. After having ...